LYEL
NASDAQLyell Immunopharma Inc.
News · 26 weeks60+57%
2026-03-012026-08-23
Mix3790d
- Insider25(68%)
- Other5(14%)
- SEC Filings5(14%)
- Analyst2(5%)
Latest news
25 items- INSIDERPresident and CEO Seely Lynn sold $149,013 worth of shares (9,589 units at $15.54), decreasing direct ownership by 13% to 63,899 units (SEC Form 4) (withholding tax)4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
- INSIDERChief Operating Officer Hill Stephen J. sold $15,369 worth of shares (989 units at $15.54), decreasing direct ownership by 6% to 16,816 units (SEC Form 4) to satisfy withholding obligation4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
- INSIDERChief Scientific Officer Lee Gary K. sold $22,642 worth of shares (1,457 units at $15.54), decreasing direct ownership by 8% to 16,220 units (SEC Form 4) to cover taxes4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
- INSIDERVP, Corporate Controller Bulis Veronica Sanchez sold $8,905 worth of shares (621 units at $14.34), decreasing direct ownership by 4% to 14,799 units (SEC Form 4) to cover withholding tax4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
- INSIDERChief Scientific Officer Lee Gary K. sold $1,879 worth of shares (131 units at $14.34), decreasing direct ownership by 0.74% to 17,677 units (SEC Form 4) (withholding tax)4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
- INSIDERChief Operating Officer Hill Stephen J. sold $1,276 worth of shares (89 units at $14.34), decreasing direct ownership by 0.50% to 17,805 units (SEC Form 4) (withholding tax)4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
- INSIDERPresident and CEO Seely Lynn sold $5,593 worth of shares (390 units at $14.34), decreasing direct ownership by 0.53% to 73,488 units (SEC Form 4) (tax liability)4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
- SECSEC Form 10-Q filed by Lyell Immunopharma Inc.10-Q - Lyell Immunopharma, Inc. (0001806952) (Filer)
- SECLyell Immunopharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Lyell Immunopharma, Inc. (0001806952) (Filer)
- PRLyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026PiNACLE pivotal clinical trial evaluating ronde-cel in 3L+ patients with LBCL on track to report additional data in second half of 2026, with pivotal data expected mid-2027 and BLA submission expected to follow in the second half of 2027Presented updated ronde-cel data in more than 100 patients with relapsed/refractory LBCL at the EHA 2026 Congress, with Phase 1/2 safety data showing no Grade ≥ 3 CRS and low rates of Grade ≥ 3 ICANS supporting potential outpatient administrationReported updated LYL273 safety data in relapsed/refractory mCRC, with gastrointestinal prophylaxis regimen and standardized safety management plan reducing Grade ≥ 2 diarrhea or colitis from 55% to 10%; amended ongoin
- ANALYSTStifel initiated coverage on Lyell Immunopharma with a new price targetStifel initiated coverage of Lyell Immunopharma with a rating of Buy and set a new price target of $36.00
- INSIDERLarge owner Innovative Cellular Therapeutics Holdings Ltd disposed of 44,000 shares, decreasing direct ownership by 2% to 2,774,980 units (SEC Form 4)4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
- INSIDERLarge owner Innovative Cellular Therapeutics Holdings Ltd disposed of 38,500 shares, decreasing direct ownership by 1% to 2,818,980 units (SEC Form 4)4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
- ANALYSTB. Riley Securities initiated coverage on Lyell Immunopharma with a new price targetB. Riley Securities initiated coverage of Lyell Immunopharma with a rating of Buy and set a new price target of $44.00
- SECSEC Form EFFECT filed by Lyell Immunopharma Inc.EFFECT - Lyell Immunopharma, Inc. (0001806952) (Filer)
- INSIDERLarge owner Innovative Cellular Therapeutics Holdings Ltd sold $137 worth of shares (10 units at $13.70), decreasing direct ownership by 0.00% to 2,857,480 units (SEC Form 4)4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
- INSIDERLarge owner Innovative Cellular Therapeutics Holdings Ltd sold $137 worth of shares (10 units at $13.73), decreasing direct ownership by 0.00% to 2,857,490 units (SEC Form 4)4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
- SECSEC Form S-3 filed by Lyell Immunopharma Inc.S-3 - Lyell Immunopharma, Inc. (0001806952) (Filer)
- INSIDERLarge owner Innovative Cellular Therapeutics Holdings Ltd disposed of 76,000 shares, decreasing direct ownership by 3% to 2,857,500 units (SEC Form 4)4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
- PRLyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual ConferenceSOUTH SAN FRANCISCO, Calif., June 25, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that members of its senior management team will participate in a fireside chat at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on Tuesday, June 30, 2026, at 1:30 pm Eastern Time. A live webcast of the fireside chat and subsequent replay can be accessed through the Investors section of the Company’s website at www.lyell.com. About Lyell Immunopharma, Inc. Lyell is a late-stage clinical company advancing a pipel
- INSIDERLarge owner Innovative Cellular Therapeutics Holdings Ltd disposed of 66,500 shares, decreasing direct ownership by 2% to 2,933,500 units (SEC Form 4)4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
- INSIDERNew insider Innovative Cellular Therapeutics Holdings Ltd claimed ownership of 3,000,000 shares (SEC Form 3)3 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
- INSIDERPresident and CEO Seely Lynn sold $7,337 worth of shares (388 units at $18.91), decreasing direct ownership by 0.52% to 73,878 units (SEC Form 4) (tax withholding)4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
- INSIDERChief Scientific Officer Lee Gary K. sold $2,460 worth of shares (130 units at $18.92), decreasing direct ownership by 0.72% to 17,808 units (SEC Form 4) (withholding obligation)4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
- INSIDERChief Operating Officer Hill Stephen J. sold $1,684 worth of shares (89 units at $18.92), decreasing direct ownership by 0.49% to 17,894 units (SEC Form 4) (tax liability)4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
LYEL FAQ
7 questionsWhat does Lyell Immunopharma Inc. do?
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845 for multiple solid tumors; and NY-ESO-1 for synovial...Where does LYEL stock trade?
Lyell Immunopharma Inc. (LYEL) is listed on NASDAQ.What sector and industry is LYEL in?
Lyell Immunopharma Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Lyell Immunopharma Inc. go public?
Lyell Immunopharma Inc. (LYEL) completed its IPO in 2021.What are analysts saying about LYEL?
Lyell Immunopharma Inc. has had 8 recent analyst actions on file. The most recent action was from Stifel: Buy with a $3600.00 price target on 2026-08-06.What companies are similar to LYEL?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare LYEL side-by-side with any of them on Quantisnow.How can I track LYEL on Quantisnow?
Quantisnow aggregates Lyell Immunopharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LYEL to receive live email and push alerts on every new disclosure.